{"id":93106,"date":"2016-12-27T13:57:03","date_gmt":"2016-12-27T13:57:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=93106"},"modified":"2016-12-27T13:57:03","modified_gmt":"2016-12-27T13:57:03","slug":"creative-biolabs-released-thousands-of-therapeutic-antibodies-for-research-use","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-released-thousands-of-therapeutic-antibodies-for-research-use_93106.html","title":{"rendered":"Creative Biolabs Released Thousands of Therapeutic Antibodies for Research Use"},"content":{"rendered":"
\"\"<\/a><\/div>\n
To meet the antibody market demands, Creative Biolabs added hundreds of therapeutic antibodies to its antibody product database.<\/div>\n

Creative Biolabs is an experienced antibody product and service provider located in New York. Over the last decade, Creative Biolabs has been providing products and services for over 26 countries, including the UK, Germany, Italy, France, etc.<\/p>\n

With years of experience in the field of antibody therapy, Creative Biolabs is now regarded as one of the leaders in the rapidly emerging market. <\/p>\n

Therapeutic antibodies<\/a> are monoclonal antibodies developed to attack specific cells or proteins for the treatment of a wide variety of diseases, including immune disorders, cancers and infections. Currently, there are 65 monoclonal antibodies approved by FDA for clinical use and more than 350 are being evaluated in clinical trials. With their great potential and existing performance, therapeutic antibody development<\/a> has entered a rapid growth phase in demand of therapeutic market.<\/p>\n

Creative Biolabs offers a full range of therapeutic antibodies currently available for research of a wide variety of diseases. “We guarantee generated endotoxin free antibodies are fully functional and ready to use in animal-based assays and clinical trials”, introduced Dr. Monica Müller, scientific officer of Creative Biolabs.<\/p>\n

“Therapeutic antibody is presented with features of high-affinity, high specificity and low off-target activity, low or non immunogenicity, long-term benefit with short-term therapy and ndotoxin free. And because of these features, we are focusing much on it”, said Dr. Monica.<\/p>\n

About Creative Biolabs<\/strong><\/p>\n

Creative Biolabs is a biotech company specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early antibody drug discovery and development, such as antibody conjugated drugs<\/a>. It has been working for a large number of clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Candy Swift
Email:<\/strong> marketing@creative-biolabs.com
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.creativebiolabs.net<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

To meet the antibody market demands, Creative Biolabs added hundreds of therapeutic antibodies to its antibody product database. Creative Biolabs is an experienced antibody product and service provider located in New York. Over the last decade, Creative Biolabs has been … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-93106","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/93106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=93106"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/93106\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=93106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=93106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=93106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}